Genta Plunges on Failed Phase III Survival Analysis for Genasense
By Trista Morrison
Tuesday, May 24, 2011
After more than a decade of development, Genta Inc. appears to be putting beleaguered antisense drug Genasense (oblimersen sodium) out of its misery.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.